Company Encyclopedia
View More
name
Allogene Therapeutics
ALLO.US
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma.
1.946 T
ALLO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking235/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-54.43%E
    • Profit Margin0.00%D
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-100.00%E
    • Net Profit YoY25.20%B
    • Total Assets YoY-25.35%E
    • Net Assets YoY-32.00%E
  • Cash ScoreD
    • Cash Flow Margin0.00%D
    • OCF YoY-100.00%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreB
    • Gearing Ratio28.30%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Allogene Therapeutics SVP and CTO Benjamin Machinas Beneski Reports Disposal of Common Shares

    Benjamin Machinas Beneski, SVP and CTO of Allogene Therapeutics Inc., reported the disposal of common shares of the company. This information was published via EDGAR by the U.S. SEC on November 19, 2025. The news is generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ALLO
    -5.26%
    Reuters·
    US
    ALLO
    -5.26%

    VP Beneski Files To Sell 786 Of Allogene Therapeutics Inc [ALLO]

    VP Beneski of Allogene Therapeutics Inc filed a Form 144 with the SEC to sell 786 restricted shares on November 17, 2025. The sale will be brokered by Morgan Stanley Smith Barney LLC. Form 144 is required for selling restricted stock, allowing sales within 90 days of filing.

    Reuters·
    US
    ALLO
    -5.26%
    Reuters·
    US
    ALLO
    -5.26%

    Binance postpones Allora (ALLO) trading opening time.

    According to an official announcement, Binance's Allora (ALLO) trading, originally scheduled to open at 13:00 (UTC) on November 11, 2025, will be postponed to 14:00 (UTC) on November 11, 2025. (This news item was generated with AI assistance.)

    CoinLive·
    US
    ALLO
    -5.26%
    CoinLive·
    US
    ALLO
    -5.26%

    Positive Outlook for Allogene Therapeutics: Buy Rating Backed by Promising Pipeline Advancements and Strong Financial Position

    Canaccord Genuity analyst John Newman has maintained a Buy rating on Allogene Therapeutics (ALLO) due to promising pipeline advancements and a strong financial position. Key upcoming data releases include proof-of-concept for ALLO-329 in autoimmune diseases and a positive futility analysis for cema-cel in DLBCL, both expected in 2026. The company has a cash balance of $277 million, projected to sustain operations until mid-2027. Piper Sandler also supports the Buy rating with a $7.00 price target.

    Tip Ranks·
    US
    ALLO
    -5.26%
    Tip Ranks·
    US
    ALLO
    -5.26%

    Allogene Therapeutics to Participate in Jefferies Global Healthcare Conference

    Allogene Therapeutics Inc. will participate in the Jefferies Global Healthcare Conference in London on November 18. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases. This announcement is for informational purposes only and should not be considered financial or legal advice.

    Reuters·
    US
    ALLO
    -5.26%
    Reuters·
    US
    ALLO
    -5.26%
    © 2025 Longbridge｜Disclaimer